Results 1 to 10 of about 156,868 (201)

Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma [PDF]

New England Journal of Medicine, 2014
Combined BRAF and MEK inhibition, as compared with BRAF inhibition alone, delays the emergence of resistance and reduces toxic effects in patients who have melanoma with BRAF V600E or V600K mutations.In this phase 3 trial, we randomly assigned 423 previously untreated patients who had unresectable stage IIIC or stage IV melanoma with a BRAF V600E or ...
Georgina V Long, Daniil Stroyakovskiy, Helen Gogas   +2 more
exaly   +4 more sources

BRAF V600E mutations in urine and plasma cell-free DNA from patients with Erdheim-Chester disease. [PDF]

, 2014
Erdheim-Chester disease (ECD) is a rare histiocytosis with a high prevalence of BRAF V600E mutation (>50% of patients). Patients with BRAF-mutant ECD can respond to BRAF inhibitors.
Cabrilo, Goran, Erlander, Mark G, Hassaine, Latifa, Holley, Veronica R, Janku, Filip, Kosco, Karena, Kurzrock, Razelle, Leppin, Lorieta, Lin, Patrick P, Meric-Bernstam, Funda, Poole, Jason C, Stepanek, Vanda M, Vibat, Cecile Rose T   +12 more
core   +16 more sources

Study on relationship between genetic abnormalities and clinicopathological features in K hospital's patients with colorectal cancer

Journal of Advanced Biotechnology and Experimental Therapeutics, 2022
The MAPK-ERK, as well as PI3K-AKT signaling transduction pathway, represents a pivotal function in tumorigenesis. Genetic alterations of potential tumor-driven genes, for instance, KRAS, BRAF, NRAS, and PIK3CA can result in uncontrolled cell ...
Linh Dieu Vuong, Ha Hoang Chu, Quang Ngoc Nguyen   +2 more
doaj   +1 more source

DETECTION OF SOMATIC MUTATIONS IN THE BRAF GENE BY PYROSEQUENCING

Сибирский онкологический журнал, 2021
Introduction. Detection of somatic mutations in the BRAF gene can be used in clinical oncology to clarify the diagnosis, select therapy and assess the prognosis of the disease.
O. P. Dribnokhodova, E. A. Dunaeva, G. V. Leshkina, E. A. Yarygina, A. Yu. Bukharina, Ya. A. Voiciehovskaya, E. V. Borisova, S. K. Bormotova, A. I. Daoud, V. N. Khlavich, K. O. Mironov   +10 more
doaj   +1 more source

Deep and lasting response and acquired resistance to BRAFV600E targeting in a low-grade ovarian cancer patient

Cancer Biology & Therapy, 2023
The treatment of BRAFV600E mutant melanoma has been revolutionized by BRAF inhibitors. Furthermore, the BRAF/MEK combination has shown further improvement in clinical outcomes in advanced and in adjuvant melanoma patients.
Sandro Anchisi, Anita Wolfer, Bettina Bisig, Edoardo Missiglia, Amine Tiab, Ehab Mohamed Kamel, Olivier Michielin, George Coukos, Krisztian Homicsko   +8 more
doaj   +1 more source

CRAF R391W is a melanoma driver oncogene. [PDF]

, 2016
Approximately 75% of melanomas have known driver oncogenic mutations in BRAF, NRAS, GNA11 or GNAQ, while the mutations providing constitutive oncogenic signaling in the remaining melanomas are not known.
Atefi, Mohammad, Avramis, Earl, Chmielowski, Bartosz, Friedman, Michael, Graeber, Thomas G, Lassen, Amanda, Le, Allison, Lomova, Anastasia, Ng, Charles, Ribas, Antoni, Titz, Bjoern, Tsoi, Jennifer   +11 more
core   +7 more sources

KRAS and BRAF Concomitant Mutations in a Patient with Metastatic Colon Adenocarcinoma: An Interesting Case Report

Case Reports in Oncology, 2020
A 68-year-old female patient with tenesmus and blood in the stool was admitted to the S.G. Moscati Hospital of Taranto. Investigations revealed infiltrative mucinous colon adenocarcinoma accompanied by lymph node metastases.
Concetta Cafiero, Agnese Re, Gerardo D’Amato, Pier Luigi Surico, Giammarco Surico, Michele Pirrelli, Salvatore Pisconti   +6 more
doaj   +1 more source

Evaluation of mutations in KRAS and BRAF genes in Iranian population with diffuse gastric cancer [PDF]

World Cancer Research Journal, 2019
OBJECTIVE: RAS proteins control signaling pathways which are the main regulators of the normal cell growth and malignant transformation cells. The point mutations in the KRAS gene are current event in numerous human cancers including pancreatic, lung ...
M. Saneipour, A. Moridnia
doaj   +1 more source

Somatic mutations in colorectal cancer: regional experience

Consilium Medicum, 2022
Introduction. Colorectal cancer is one of the most common malignant neoplasms in economically developed countries, ranking 3rd and 2nd in the structure of morbidity and mortality, respectively. Current knowledge about the molecular features of colorectal
Nikolai A. Ognerubov, Elena N. Ezhova
doaj   +1 more source

Prognostic value of somatic mutation testing and different methods of treatment of low-risk differentiated thyroid cancer [PDF]

Эндокринная хирургия, 2019
Background: Using molecular testing for prediction the course of the disease could possibly help doctors in making therapeutic decisions about the management of patients, because it remains controversial issues in low-risk differentiated thyroid cancer ...
Vera A. Kachko, Vladimir E. Vanushko, Nadezhda M. Platonova   +2 more
doaj   +1 more source